Aurobindo Pharma Q4 FY26 Earnings Preview & Outlook

Aurobindo Pharma Q4 Results 2026 Preview

• Aurobindo Pharma Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-16% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 13-19% YoY.
• EBITDA to rise 15%.
• Aurobindo Pharma is expected to show Moderate Growth Expected in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

Aurobindo Pharma Share Performance

• Over the past six months, Aurobindo Pharma share price has Up by 14-20% to 1320.3.
• Moreover, over the past year, the stock has Up by 28%
• Despite this weak short-term performance, Aurobindo Pharma stock has delivered a financially sound 210% return over the past 5 years.
• As of today, 25-03-2026, the Aurobindo Pharma share price is trading at 1320.3 per share.

Key Factors to Watch for Aurobindo Pharma Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

Visit Univest app or website to check more Aurobindo Pharma latest news to make an informed investment decision. 

About Aurobindo Pharma

Aurobindo Pharma manufactures generic pharmaceuticals and APIs for global markets. The company benefits from strong presence in regulated markets and focuses on expanding product pipeline.

Visit Univest app or website to check more Aurobindo Pharma latest news to make an informed investment decision. 

Final Thoughts

Aurobindo Pharma is gear up to announce its Q4 FY26 results. Analysts expect 11-16% revenue growth, a 13-19% rise in PAT, and a 15% rise in EBITDA. Aurobindo Pharma focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Aurobindo Pharma Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Atlanta Electricals Q4 FY26 Results Preview & Outlook

ATLANTAA Q4 FY26 Earnings Preview & Outlook

Allcargo Terminals Q4 FY26 Results Preview & Outlook

Ather Energy Q4 FY26 Earnings Preview & Outlook

Adani Total Gas Q4 FY26 Results Preview & Outlook